Phase I trial of autologous regulatory T cells for immune aplastic anemia.
Nazia Matto, Shreyans Gandhi, Marta Rzepkowska et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase I clinical trial evaluated autologous regulatory T-cell (Treg) therapy in six patients with immune aplastic anemia resistant or refractory to standard treatment. Treg were collected, expanded under Good Manufacturing Practice conditions, and given in two doses of 5×106/ kg, 2 weeks apart. Cells were successfully expanded for all six patients, with no adverse or immune-related events reported. Hematologic responses occurred in three patients. Analyses also tracked infused-cell persistence and identified associations between post-infusion Treg clusters and clinical efficacy.
Key findings
- Treg were expanded to the required dose for all six patients, with no adverse or immune-related events reported.
- Hematologic responses were observed in three patients.
- Post-infusion Treg clusters accumulated in association with clinical efficacy; infusion-product phenotypic markers correlated with in vivo expansion.
Why it matters
The findings provide early clinical evidence that autologous Treg can be manufactured and infused in patients with treatment-resistant immune aplastic anemia, while also offering a potential way to modulate abnormal immune activity. The observed responses and cell-tracking results support further evaluation, but the small phase I trial establishes feasibility and preliminary safety rather than definitive efficacy.
What to keep in mind
The trial included only six patients and was a phase I study; the abstract does not report a comparator group.